FDA: Zofran 32-mg Dose Pulled From Market

The anti-nausea drug may cause serious heart problems at that dosage

WEDNESDAY, Dec. 5 (HealthDay News) -- The 32-mg, single intravenous dose of Zofran (ondansetron), an anti-nausea drug, is being removed from the market due to its potential to cause serious, even fatal, cardiac damage, according to a Drug Safety Communication (DSC) issued Dec. 4 by the U.S. Food and Drug Administration.

The agency issued a prior DSC in late June 2012 recommending that this particular dose of Zofran be avoided due to the risk of prolonged QT interval, which can lead to torsades de pointes, a potentially fatal heart rhythm.

The FDA does continue to recommend Zofran administered intravenously at 0.15 mg/kg every four hours for patients experiencing chemotherapy-related nausea and vomiting, with no single dose exceeding 16 mg. The agency is working with manufacturers of all branded and generic 32-mg intravenous ondansetron injectable products to recall them from the market and anticipates the product will be removed through early 2013.

According to a press release issued by the agency, the FDA "does not anticipate that removal of the 32-mg intravenous dose of ondansetron currently sold as pre-mixed injections will contribute to a drug shortage of intravenous ondansetron, as the 32-mg dose makes up a very small percentage of the current market."

More Information

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events